+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 44 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.

Age: 50Years - 85YearsAll GendersPhase 2
80 locations
R

Actively Recruiting

Healthy Volunteer

This research aims to compare how the body processes the drug MK-1406 when given as two injections versus three injections in healthy adult participants. The study also evaluates the safety and how well participants tolerate MK-1406. It is a Phase 1 clinical trial designed to gather important early information about the drugs behavior and effects. Participants receive MK-1406 through subcutaneous injections administered either as three injections or two injections on the first day of the study. The study uses a randomized, open-label, parallel group design, meaning participants are randomly assigned to one of the two groups and both researchers and participants know which treatment is given. During the study, researchers monitor participants for up to four weeks after dosing to measure how much MK-1406 is in the blood over time and observe any side effects or injection site reactions. Participants are followed for about 43 days to record any adverse events or if they stop the study due to side effects. Safety and tolerability are carefully assessed throughout the trial.

Age: 18Years - 64YearsAll GendersPhase 1
7 locations
O

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.

Age: 18Years - 65YearsAll GendersPhase 2
45 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.

Age: 55Years +All GendersPhase Not Applicable
125 locations
E

Actively Recruiting

Researchers are studying metabolic dysfunction-associated steatohepatitis MASH in adults to evaluate the effects of two drugs, ECC4703 and ECC0509, alone and combined, on reducing liver fat. This phase 2a trial compares low and high doses of these drugs against placebo to understand their impact on liver fat reduction using MRI scans over 12 weeks. Participants receive oral capsules of ECC4703, ECC0509, their combination, or placebo. The study lasts 12 weeks, during which liver fat content and other related health markers are measured and compared across groups. The trial is randomized and double-blind, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants undergo MRI scans, blood tests, and biomarker assessments to monitor liver fat and overall liver health. Measurements include liver enzymes, fibrosis scores, cholesterol, glucose levels, and quality of life questionnaires. Drug levels are also tracked at multiple time points. The trial requires adults aged 18 to 75 with confirmed MASH and stable health to participate.

Age: 18Years - 75YearsAll GendersPhase 2
68 locations
E

Actively Recruiting

Researchers are evaluating the safety and tolerability of the investigational drug LTX-001 in adults aged 18 to 55 years who have schizophrenia experiencing a recent worsening of symptoms, known as an acute exacerbation. The study also aims to understand how the drug moves through the body pharmacokinetics, its early effects on schizophrenia symptoms, and changes in blood markers after taking LTX-001. Different dose levels of LTX-001 will be compared to a placebo to identify any differences in treatment effects. Eligible participants will stay in a research unit for about 35 nights, or up to 49 nights if a washout period from antipsychotic medications is needed, with three visits to the study site. During this time, they will receive oral doses of LTX-001 once or twice daily at specified amounts, or a placebo, under close monitoring. The study includes a follow-up visit one week after the overnight stay period. Participants will undergo a variety of assessments including medical history reviews, physical and neurological exams, heart electrical activity tests ECGs, blood and urine collections, and psychiatric evaluations using several standardized scales. Eye exams and brain wave recordings qEEG will also be conducted. Researchers will monitor safety through vital signs, neurological symptoms, suicidality risk, and other physical assessments from screening through day 42. The study will last about six weeks from screening to final follow-up.

Age: 18Years - 55YearsAll GendersPhase 1
10 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and tolerability of LY4006895, a study drug, in both healthy volunteers and participants with early symptomatic Alzheimers Disease AD. The study includes two parts Part A involves single-ascending doses in healthy participants, and Part B involves multiple-ascending doses in participants with early AD. The study aims to better understand how LY4006895 behaves in the body, including how much enters the bloodstream and how long it takes to be eliminated. Participants in Part A will receive single intravenous IV doses of LY4006895 or a placebo, while those in Part B will receive multiple IV doses of LY4006895 or placebo. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. The entire study lasts approximately 29 weeks for Part A and 61 weeks for Part B, including screening periods. During the study, participants will have blood tests to measure drug levels and monitor safety. Researchers will track any treatment-related side effects, serious adverse events, and study discontinuations. Participants with early AD must have study partners who will assist with visits and provide consent. The primary outcome is the number of participants experiencing adverse events up to 61 weeks. The study includes regular assessments to ensure participant safety and gather pharmacokinetic data throughout the trial.

Age: 45Years - 85YearsAll GendersPhase 1
13 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the study drug Seltorexant compared with a placebo in adults and elderly participants with major depressive disorder MDD, a common mood disorder marked by persistent sadness and loss of interest. This Phase 3 study includes a double-blind treatment phase to measure improvement in depressive symptoms specifically in participants with moderate-to-severe insomnia symptoms. The study also aims to assess long-term safety and tolerability of Seltorexant in an open-label treatment phase. During the double-blind phase, participants will take either a Seltorexant tablet or a matching placebo once daily for 42 days. Those who qualify for the open-label phase will continue taking Seltorexant daily for up to 6 months. The study compares the two groups to understand how well Seltorexant works alone in treating MDD. Participants will undergo clinical assessments including depression rating scales, sleep disturbance questionnaires, and safety evaluations such as vital signs, laboratory tests, electrocardiograms, and suicidality ratings. Researchers will also monitor withdrawal symptoms and sexual functioning during the open-label phase. The total participation duration may extend over several months to evaluate both efficacy and long-term safety outcomes.

Age: 18Years - 74YearsAll GendersPhase 3
53 locations
E

Actively Recruiting

Researchers are studying people with opioid use disorder OUD who have trouble falling or staying asleep. This trial evaluates the safety and tolerability of suvorexant, a medication being tested to see if it helps people with OUD sleep longer compared to a placebo, which looks like the medicine but contains no active drug. The study is a Phase 3, randomized, double-blind trial led by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either suvorexant or a matching placebo for up to about 8 weeks. Those in the suvorexant group start with 10 mg for the first three nights, which may be increased to 20 mg nightly at the investigators discretion. The placebo group receives an identical-looking pill with no active medication. The study compares sleep duration and monitors safety during this period. During the study, participants will be assessed for changes in total sleep time and wakefulness after sleep onset at baseline and at week 8. Researchers will track adverse events, serious side effects, and any treatment discontinuations due to side effects throughout up to 10 weeks. Substance abuse will be monitored at several time points. Participants will complete study visits and safety assessments to help understand how the medication affects sleep and overall health.

Age: 18Years - 70YearsAll GendersPhase 3
13 locations
R

Actively Recruiting

Schizophrenia is a serious psychiatric condition that affects thinking, language, perception, and self-awareness. Researchers are studying an investigational oral drug called emraclidine in adults with schizophrenia to assess its safety, how it moves through the body, and its effect on disease activity. This phase 2 trial involves about 268 participants across multiple sites in the United States. Participants are divided into two parts Part A and Part B. In Part A, participants receive oral emraclidine or placebo for either 14 days or up to 21 days depending on the dosing schedule, which may include a titration period. In Part B, participants receive oral emraclidine or placebo for 42 days. Following treatment, all participants enter a 30-day safety follow-up period to monitor any adverse effects. During the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and side effect monitoring. Researchers also collect questionnaire data to evaluate changes in symptoms. The trial measures adverse events and detailed drug levels in the blood, along with clinical scales assessing symptom severity and improvement. Total participation lasts up to approximately 74 days, including treatment and follow-up.

Age: 18Years - 65YearsAll GendersPhase 2
7 locations

1-10 of 44

1